Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV000681632 | SCV000809076 | likely pathogenic | Bloom syndrome | 2018-04-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001020308 | SCV001181768 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-09-03 | criteria provided, single submitter | clinical testing | The p.K1147* pathogenic mutation (also known as c.3439A>T), located in coding exon 17 of the BLM gene, results from an A to T substitution at nucleotide position 3439. This changes the amino acid from a lysine to a stop codon within coding exon 17. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Greenwood Genetic Center Diagnostic Laboratories, |
RCV000681632 | SCV002583684 | likely pathogenic | Bloom syndrome | 2022-09-08 | criteria provided, single submitter | clinical testing | PVS2 PM2 |
Labcorp Genetics |
RCV000681632 | SCV003028913 | pathogenic | Bloom syndrome | 2024-06-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys1147*) in the BLM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BLM are known to be pathogenic (PMID: 17407155). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BLM-related conditions. ClinVar contains an entry for this variant (Variation ID: 562196). For these reasons, this variant has been classified as Pathogenic. |